Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1948
https://www.valueinhealthjournal.com/article/S1098-3015(17)32282-9/fulltext
Title :
Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32282-9&doi=10.1016/j.jval.2017.08.1948
First page :
A723
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1773